

1 **Title: Estimated incidence rate of specific cardiovascular**  
2 **and respiratory hospitalizations attributable to**  
3 **Respiratory Syncytial Virus among adults in Germany**  
4 **between 2015 and 2019**

5

6 **Author Details:**

7 Caihua Liang<sup>1</sup>, Aleksandra Polkowska-Kramek<sup>2</sup>, Caroline Lade<sup>3</sup>, Lea Johanna  
8 Bayer<sup>3</sup>, Robin Bruyndonckx<sup>2</sup>, Bennet Huebbe<sup>3</sup>, Worku Biyadgie Ewnetu<sup>2</sup>, Pimnara  
9 Peerawaranun<sup>2</sup>, Maribel Casas<sup>2</sup>, Thao Mai Phuong Tran<sup>2</sup>, Gordon Brestrich<sup>3</sup>,  
10 Christof von Eiff<sup>3</sup>, Bradford D. Gessner<sup>1</sup>, Elizabeth Begier<sup>4</sup>, Gernot Rohde<sup>5</sup>

11

12 **Affiliations:**

13 <sup>1</sup> Pfizer Inc-New York (USA)

14 <sup>2</sup> P95 Epidemiology & Pharmacovigilance, Leuven, Belgium

15 <sup>3</sup> Pfizer Pharma GmbH - Berlin (Germany)

16 <sup>4</sup> Pfizer Inc - Dublin (Ireland)

17 <sup>5</sup> Goethe University Frankfurt, University Hospital, Medical Clinic I, Department of  
18 Respiratory Medicine, Frankfurt/Main, Germany

19

20 **Corresponding author:**

21 Caihua Liang

22 Email: [caihua.liang@pfizer.com](mailto:caihua.liang@pfizer.com)

23 Address: 66 Hudson Blvd E, New York, NY 10001

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## 24 **Abstract**

25 **Introduction:** Respiratory syncytial virus (RSV) can cause severe outcomes among  
26 adults. However, RSV incidence in adults is frequently underestimated due to non-  
27 specific symptomatology, limited standard-of-care testing, and lower test sensitivity  
28 compared to infants. We conducted a retrospective observational study to estimate  
29 RSV-attributable incidence of hospitalizations among adults in Germany between 2015  
30 and 2019.

31 **Methods:** Information on hospitalizations and the number of people at risk of  
32 hospitalization (denominator) was gathered from a Statutory Health Insurance (SHI)  
33 database. A quasi-Poisson regression model accounting for periodic and aperiodic time  
34 trends and virus activity was fitted to estimate the RSV-attributable incidence rate  
35 (IR) of four specific cardiovascular hospitalizations (arrhythmia, ischemic heart  
36 diseases, chronic heart failure exacerbations, cerebrovascular diseases) and four  
37 specific respiratory hospitalizations (influenza/pneumonia, bronchitis/bronchiolitis,  
38 chronic lower respiratory tract diseases, upper respiratory tract diseases).

39 **Results:** RSV-attributable IRs of hospitalizations were generally increasing with age.  
40 Among cardiovascular hospitalizations in adults aged  $\geq 60$  years, arrhythmia and  
41 ischemic heart diseases accounted for the highest incidence of RSV-attributable  
42 events, followed by chronic heart failure exacerbation, with annual IR ranges of 157–  
43 260, 133–214, and 105–169 per 100,000 person-years, respectively. The most  
44 frequent RSV-attributable respiratory hospitalizations in adults aged  $\geq 60$  years were  
45 for chronic lower respiratory tract diseases and bronchitis/bronchiolitis, with annual IR  
46 ranges of 103–168 and 77–122 per 100,000 person-years, respectively.

47 **Conclusion:** RSV causes a considerable burden of respiratory and cardiovascular  
48 hospitalizations in adults in Germany, similar to other respiratory viruses (e.g.,

49 influenza and SARS-CoV-2). This highlights the need to implement effective  
50 prevention strategies, especially for older adults.

## 51 **Keywords:**

52 RSV, cardiorespiratory, hospitalization, Germany, quasi-Poisson, time-series modeling

## 53 **Key Summary Points:**

- 54 • Respiratory syncytial virus (RSV) disease burden in adults is significant yet  
55 often remains unrecognized due to unspecific symptoms, lack of routine testing  
56 and lower test sensitivity compared to infants.
- 57 • Using a quasi-Poisson regression time-series model, we estimated the age-  
58 stratified RSV-attributable incidence of specific cardiovascular and respiratory  
59 hospitalizations in Germany between 2015 and 2019.
- 60 • Estimated cardiorespiratory RSV hospitalization rates increased with age and  
61 were significantly higher in older adults.
- 62 • Arrhythmia, ischemic heart diseases, and chronic lower respiratory tract  
63 disease exacerbation were the most frequent causes of RSV-attributable  
64 cardiovascular and respiratory hospitalizations.
- 65 • RSV causes a considerable burden of respiratory and cardiovascular  
66 hospitalizations among adults in Germany, and effective RSV vaccines could  
67 improve public health outcomes, especially for older adults.

## 68 **Introduction**

69 Respiratory syncytial virus (RSV) usually causes mild respiratory infections but  
70 may also lead to severe lower respiratory tract diseases such as chronic  
71 obstructive pulmonary disease exacerbation and pneumonia (1). RSV affects  
72 people of any age, but the risk of severe infections and hospitalizations is highest  
73 among infants, adults aged 60 years and above, and those with comorbidities (1-  
74 4).

75 The incidence rate (IR) and clinical burden of RSV disease in adults are  
76 challenging to measure due to symptoms resembling influenza and other co-  
77 circulating respiratory viruses (5). Limited standard-of-care RSV testing among  
78 adults, single specimen collection (i.e., use of nasopharyngeal/nasal swab only)  
79 and reduced sensitivity of diagnostic testing compared to children (6-9) contribute  
80 to the underestimation of the RSV burden. Additionally, inadequate RSV diagnostic  
81 capacity in many healthcare facilities (5, 8, 10, 11) and low awareness of RSV,  
82 particularly for patients with cardiopulmonary manifestations, hinder measuring  
83 the actual RSV burden (12). Further, even when RSV is diagnosed via laboratory  
84 testing, other non-specific acute respiratory infection codes may be used for  
85 administrative diagnoses (13).

86 RSV-associated exacerbation of underlying cardiopulmonary diseases may  
87 contribute to a large and unrecognized burden of RSV disease (12). Several  
88 studies demonstrated that RSV can cause exacerbation of asthma and chronic  
89 obstructive pulmonary disease (COPD) (14-17) (18). Growing evidence indicates  
90 that RSV is associated with cardiovascular diseases such as acute myocardial  
91 infarction, stroke, arrhythmia, exacerbation of congestive heart failure (CHF), and

92 coronary artery disease (CAD) (12, 19-26). Nonetheless, data on RSV-attributable  
93 cardiovascular hospitalizations in adults is limited.

94 Due to severe under-ascertainment of RSV cases in adults, the recent burden of  
95 RSV estimates is more commonly based on mathematical models. Those models  
96 relate the temporal variability of the community activity of RSV (indicated by, e.g.,  
97 week-to-week RSV disease case counts) to the variability in disease outcomes that  
98 may be caused or triggered by an RSV infection (e.g., COPD exacerbation  
99 hospitalizations and cardiovascular hospitalizations). Among those outcomes, the  
100 model estimates the portion expected to be RSV-attributable (10, 27-29).

101 In Germany, data on the RSV burden from prospective observational incidence  
102 studies are unavailable (30), but a recent model-based study showed considerable  
103 RSV morbidity and mortality between 2015 and 2019 (31). The estimated RSV-  
104 attributable hospitalization IRs increased with age, with high rates observed  
105 among people 60 years and above (respiratory diseases: 236–363 per 100,000  
106 person-years; cardiovascular diseases: 558–885 per 100,000 person-years; and  
107 cardiorespiratory diseases: 584–912 per 100,000 person-years) (31). However,  
108 detailed data on RSV-attributable hospitalizations in more specific respiratory and  
109 cardiovascular subgroups are still lacking.

110 Providing such estimates would help to better understand the burden imposed by  
111 RSV and guide the formulation of vaccine policies. Lately, RSV vaccines have been  
112 licensed to prevent lower respiratory tract disease caused by RSV in adults 60  
113 years and above. Two RSV vaccines [GSK's RSV Arexvy vaccine (32) and Pfizer's  
114 RSV Abrysvo vaccine (33)] for adults aged 60 years and above have been  
115 available in Germany since 2023. In 2024, market authorization received a third  
116 RSV vaccine [Moderna's mRESVIA vaccine] (34).

117 We conducted a model-based study to estimate RSV-attributable hospitalizations  
118 of four respiratory (influenza/pneumonia, bronchitis/bronchiolitis, chronic lower  
119 respiratory tract diseases, upper respiratory tract diseases) and four  
120 cardiovascular (chronic heart failure exacerbation, ischemic heart diseases,  
121 arrhythmia, cerebrovascular diseases) conditions in Germany.

## 122 **Methods**

### 123 **Study design**

124 We conducted an observational retrospective study to estimate the IRs of specific  
125 respiratory and cardiovascular hospitalizations attributable to RSV among adults in  
126 Germany using a quasi-Poisson regression model.

### 127 **Data sources**

128 Data on hospitalizations was sourced from the Deutsche Analysedatenbank für  
129 Evaluation und Versorgungsforschung (DADB) database from Gesundheitsforen  
130 Leipzig (GFL). This database contains Statutory Health Insurance (SHI) data of  
131 approximately 3.5 million insured individuals. Participants included in the study  
132 were adults aged 18 years and above. The age and sex structure of the DADB  
133 database is similar to that of the German population, with adjustment factors to  
134 account for a slightly younger population in DADB available (35). The study  
135 period, from 2015 to 2019, was selected to avoid any distortions in RSV  
136 epidemiology due to the COVID-19 pandemic (36).

137 The study included eight disease outcomes, coded according to the German  
138 Modification (GM) of the International Classification of Diseases, 10<sup>th</sup> revision  
139 (ICD-10-GM). These include four specific respiratory outcomes [influenza/  
140 pneumonia (J10-J18), bronchitis/bronchiolitis (J20-J22), chronic lower respiratory  
141 tract diseases (J40-J47), upper respiratory tract diseases (J00-J06, J30-J39)], and

142 four specific cardiovascular outcomes [chronic heart failure (I42-I43, I50, I51.7),  
143 ischemic heart diseases (I20-I25), arrhythmias (I44-I49), and cerebrovascular  
144 diseases (I60-I68)]. To compare the difference between the number of observed  
145 (reported in the database) and attributable (model-based) RSV events, we  
146 obtained RSV-specific hospitalizations (B97.4, J21.0, J12.1, J20.5) stratified by  
147 age group.

148 Hospitalization was defined as an overnight stay in a hospital commencing from  
149 the admission date. If subsequent hospitalizations for the same outcome occurred  
150 within 30 days from discharge, these were collapsed with the initial hospitalization  
151 to avoid overcounting cases due to readmission.

152 Individuals were categorized into four age groups: 18-44, 45-59, 60-74, and 75  
153 years and above. The 60-year and above cut-off was selected because RSV  
154 vaccines are approved for this age group in Germany. For anonymization  
155 purposes, data were suppressed if fewer than 5 cases were reported in the age  
156 group and outcome stratum.

157 The indicator for RSV circulation was defined as the weekly number of RSV-related  
158 hospitalizations in children under two years of age (ICD-10-GM codes: B97.4,  
159 J21.0, J12.1, J20.5, J21.9). As in other studies (10, 26, 28, 37), we selected RSV  
160 circulation in children due to the higher frequency of testing and hospitalization in  
161 this age group and the higher sensitivity of diagnostic tests compared to adults (8,  
162 38). As most bronchiolitis cases in young children are caused by RSV, we also  
163 included J21.9 (acute bronchiolitis, unspecified) (39-41) as a proxy for RSV  
164 circulation. The indicator for influenza circulation was defined as the weekly  
165 number of influenza-specific hospitalizations (ICD-10-GM codes: J09, J10, J11) in  
166 adults aged 60 years and above (37).

## 167 **Statistical analysis**

168 Upon observation of seasonality, age-group-stratified weekly aggregated data  
169 were modeled using a quasi-Poisson regression model. The model was constructed  
170 according to the previously published protocol (42). The model accounts for  
171 baseline periodic and aperiodic time trends, viral activity (RSV and influenza) and  
172 potential overdispersion.

173 With these fitted models, we obtained the annual number of RSV-attributable  
174 events and the proportion of RSV-attributable events for each outcome and age  
175 group as described in the protocol (42).

176 Yearly IRs of RSV-attributable events, expressed in the number of events per  
177 100,000 person-years, were obtained by dividing the annual model-based number  
178 of RSV-attributable events by the population at risk. This age-specific population  
179 at risk of the event was obtained from the DADB database. No effort was made to  
180 limit the denominator to persons at risk for the given condition (e.g., estimate  
181 COPD exacerbation incidence only among persons with COPD diagnosis). Because  
182 the DADB database, from which our estimates were obtained, has a slightly  
183 younger population compared to the overall German population covered by SHI,  
184 the yearly RSV-attributable events were multiplied with age-specific correction  
185 factors based on data provided by GFL to scale the IRs to a nationally  
186 representative level.

187 Confidence intervals were obtained via residual bootstrapping. All data  
188 management and statistical analyses were conducted using R software (version  
189 4.0.4).

190

191

## 192 **Ethical considerations**

193 This study used aggregated and anonymized data, therefore not requiring  
194 approval from Institutional Review Boards or Ethical Committees or informed  
195 consent from patients. The study was conducted following legal and regulatory  
196 requirements and research practices described in the Good Epidemiological  
197 Practice guidelines issued by the International Epidemiological Association (43).

198

## 199 **Results**

### 200 **Observed hospitalizations**

201 Between 2015 and 2019, the diagnoses with the largest number of  
202 hospitalizations were due to arrhythmia and ischemic heart diseases, responsible  
203 for 266,463 and 259,052 hospitalizations, respectively. Among respiratory  
204 hospitalizations, chronic lower respiratory tract diseases were responsible for  
205 162,344 hospitalizations, with influenza/pneumonia (74,064 hospitalizations)  
206 accounting for the most (Supplementary Table 1). The majority of hospitalizations,  
207 amounting to 70% or more, involved individuals aged 60 years and above. The  
208 exception to this trend was observed in upper respiratory tract diseases, where  
209 most hospitalizations (74% or more) occurred in younger adults aged 18-59  
210 years.

211 The reported number of RSV-specific hospitalizations based on ICD code  
212 diagnoses alone throughout the study period was 24 cases across all age groups.  
213 However, the total number of RSV-specific hospitalizations is unknown as, during  
214 most weeks in which RSV-specific hospitalizations were reported, counts were  
215 below five and hence suppressed for anonymity.

216

## 217 **Estimated RSV-attributable hospitalizations**

218 The estimated IR of RSV-attributable diseases showed year-to-year fluctuations,  
219 with the highest incidence observed for most outcomes in 2017. Due to a lack of  
220 adequate seasonal fluctuations, several outcomes were not modeled in the  
221 youngest age group. For cerebrovascular diseases, only data for the age group 75  
222 years and above were suitable for modeling (Table 1 and Table 2).

223 The estimated IR of RSV-attributable respiratory hospitalizations in the age group  
224 60 years and above was highest for chronic lower respiratory tract diseases (range  
225 across the study period: 103-168 hospitalizations per 100,000) and bronchitis/  
226 bronchiolitis (77-122 hospitalizations per 100,000) (Table 1). The IRs of RSV-  
227 attributable bronchitis/bronchiolitis hospitalizations for those aged 75 years and  
228 above were approximately 11- to 12-fold and 32- to 43-fold higher than the rates  
229 for adults aged 60-74 years and 45-59 years, respectively. Similarly, the rates of  
230 chronic lower respiratory diseases were approximately 3- to 4-fold and 12- to 15-  
231 fold higher in the oldest age group ( $\geq 75$  years) compared to younger age groups  
232 (60-74 and 45-59 years) (Table 1).

233 RSV-attributable proportions were comparable between age groups and  
234 respiratory subgroups (range 1-5% in age groups 45-59 years and 60-74 years,  
235 and 3-8% in  $\geq 75$  years) with the exception of bronchitis or bronchiolitis where the  
236 RSV-attributable proportion was 1-10% for younger age groups and 17-25% for  
237 adults 75 years and above (Table 1). For cardiovascular causes, arrhythmia (157-  
238 260 per 100,000 person-years) and ischemic heart diseases (133-215 per  
239 100,000 person-years), followed by chronic heart failure (105-169 per 100,000  
240 person-years) showed the highest RSV-attributable IRs (Table 2) in adults aged  
241  $\geq 60$  years. The RSV-attributable IRs were notably higher in older age groups,  
242 particularly among hospitalized individuals aged 75 years and above. The rates of

243 RSV-attributable arrhythmia and ischemic heart disease hospitalizations for those  
244 aged 75 and above were both approximately 4-fold higher than the rates for  
245 adults aged 60-74 years. Moreover, these rates were about 25-fold and 21-fold  
246 higher, respectively, than for adults aged 45-59 years (Table 2). RSV-attributable  
247 proportions were comparable between age groups and cardiovascular subgroups,  
248 accounting for approximately 1% to 3% of all hospitalizations (Table 2).

249

## 250 **Discussion**

251 Our study complements the results of the first model-based study in Germany  
252 (31) by providing estimates on specific types of cardiorespiratory hospitalizations  
253 attributable to RSV. We found a high burden of cardiovascular hospitalizations  
254 related to RSV, with RSV-attributable IRs for arrhythmia (157-260 per 100,000  
255 person-years) and ischemic heart diseases (133-215 per 100,000 person-years)  
256 being the two highest among all studied conditions in adults aged 60 years and  
257 above. Among respiratory conditions, chronic lower respiratory tract diseases  
258 (103-168 per 100,000 person-years) and bronchitis/bronchiolitis (77-122 per  
259 100,000 person-years) had the highest RSV-attributable incidences in adults aged  
260 60 years and over. As in other studies, we found that RSV-attributable IRs were  
261 increasing with age, with a considerable surge observed in patients aged 60 years  
262 and older. Our findings were considerably higher than those based on RSV-specific  
263 ICD-10 codes alone, suggesting vast under-ascertainment of RSV cases in adults.  
264 Substantially lower RSV hospitalization rates in adults aged >59 years (0.11-  
265 11.36 per 100,000 person-years) were also reported in an observational study in  
266 Germany, which was based on data on primary discharge diagnosis of RSV (J21.1,  
267 J20.5, J21.0) (44).

268 Our study adds to the growing evidence of the association between RSV circulation  
269 and cardiovascular events. We found that approximately 2% to 3% of  
270 hospitalizations due to arrhythmia, ischemic heart diseases, and chronic heart  
271 failure in people 60 years and above were attributed to RSV. In the oldest age  
272 group (75 years and above), we also found an association – in line with another  
273 study – between RSV and cerebrovascular diseases, with 1% to 2% of those  
274 hospitalizations being attributable to RSV. For instance, in Spain, the RSV-  
275 attributable proportion of ischemic heart diseases in adults aged 60 years and  
276 above (3%) and cerebrovascular diseases in adults aged 80 years and above (2%)  
277 were comparable to our results (26). Although the RSV-attributable proportions  
278 were comparable, it resulted in higher IRs, most likely due to overall higher  
279 observed hospitalizations due to cardiovascular causes in Germany. This might be  
280 related to different coding practices or different prevalence of comorbidities in  
281 those two populations.

282 Several mechanisms are considered to explain the relationship between RSV and  
283 cardiovascular events. Part of those conditions may be related to the indirect  
284 effect of inflammation due to acute respiratory infections. Inflammation may  
285 increase the concentration of C-reactive protein, inflammatory cytokines and  
286 clotting factors such as fibrinogen, leading to an increased risk of thrombotic  
287 coronary occlusion (20, 45, 46). Additionally, it may cause endothelial dysfunction  
288 and inhibit the function of vasodilating nitric oxide or prostaglandins, contributing  
289 to arterial and venous thromboembolic disease (47). Development of pulmonary  
290 hypertension may lead to secondary myocardial dysfunction, hypotension and  
291 arrhythmia (24). RSV can also directly infect organs, as it was isolated from  
292 myocardial tissue biopsies in patients with myocarditis (19, 24). Cardiovascular  
293 diseases remain the leading cause of morbidity and mortality worldwide (48).

294 Thus, the potential impact of a vaccine preventing cardiovascular events, as  
295 observed for the influenza vaccine (49, 50), might be substantial.

296 Our estimates for RSV-attributable hospitalizations due to bronchitis/ bronchiolitis  
297 (77-122 per 100,000) and influenza/pneumonia diagnosis grouping (67-98 per  
298 100,000) in adults aged 60 years and above align with the study conducted in  
299 Spain (100-110 per 100,000 and 83-91 and, respectively) (26). The Spanish  
300 study utilized the same generic protocol that we used for this study. In contrast,  
301 when compared to another model-based study from the United Kingdom, IRs in  
302 older age groups (65-74 and  $\geq 75$  years) were considerably higher in Germany  
303 (10). The possible reason is using different methods (quasi-Poisson regression  
304 modeling weekly counts vs linear regression modeling weekly outcome rates) and  
305 a different RSV proxy definition (weekly hospitalizations due to RSV vs weekly RSV  
306 counts from the surveillance system). We used RSV hospitalization data as a  
307 proxy because hospitalization data is less affected by the testing practices than  
308 the surveillance data, which will be mostly driven by influenza (data not shown).  
309 Further, the UK study used primary diagnosis codes, which have been shown to  
310 underestimate incidence in validation studies (51).

311 Among age groups 45-59 and 60-74 years, the highest RSV-attributable IR was  
312 revealed for chronic lower respiratory tract diseases. Respiratory viruses, including  
313 RSV, are known causes of exacerbation of COPD (16). In prospective cohort  
314 studies, approximately 4% to 11% of COPD patients tested positive for RSV (52,  
315 53). The prevalence of COPD is increasing globally, leading to enormous  
316 healthcare costs and high mortality (54, 55). Exacerbation of COPD is associated  
317 with an accelerated decline in lung function, progression of the disease and lower  
318 quality of life (15). Thus, preventing COPD exacerbation should be a public health  
319 priority, and vaccination of COPD patients should be prioritized, as suggested by

320 the recent recommendation from the US Centers for Disease Control and  
321 Prevention (56).

322 Our study showed considerable under-ascertainment of RSV cases in adults in  
323 Germany. Other studies also observed low testing activity and considerable  
324 underestimation of the RSV burden in adults (8, 9, 26) when only RSV-specific  
325 ICD codes are used. These findings highlight the need for systematic testing and  
326 reporting, including patients presenting with cardiovascular manifestations or  
327 exacerbation of underlying respiratory diseases.

328 The main strength of our study was the use of a large database of approximately  
329 3.5 million insured persons, an extended study period of five years and the  
330 inclusion of eight different medical conditions, allowing for a more sensitive  
331 estimation of the RSV burden. In addition, our study was based on a generic  
332 protocol (42) that permits robust comparisons between countries. The protocol  
333 was developed based on an extensive prior literature review and experts' input.

334 We also acknowledge some study limitations. Our model included only RSV and  
335 influenza as viral indicators, assuming those are the only pathogens related to the  
336 outcome of interest. However, by inclusion of the periodic component and  
337 overdispersion parameter, we indirectly accounted for other potentially relevant  
338 pathogens. Second, RSV hospitalizations in children less than two years old as the  
339 RSV indicator may not fully reflect viral activity in adults. However, the pattern in  
340 adults is similar to that observed in children, and for the model performance, the  
341 most important factor is the fluctuation over time rather than the absolute  
342 numbers. Third, although the SHI database is representative of the German  
343 population, the age distribution is slightly skewed towards young individuals. To  
344 account for this difference, we used correction factors to standardize for age in the  
345 incidence calculation. Lastly, we did not limit the population denominators to those

346 individuals at risk of a specific condition (e.g., limit the denominator for the RSV-  
347 attributable COPD events to those with COPD diagnosis), which would likely  
348 increase the reported incidence rate.

349 In conclusion, our study showed a high and largely unrecognized cardiovascular  
350 and respiratory burden of RSV among adults in Germany. Substantial  
351 underestimation of RSV cases emphasizes the need for standard-of-care testing,  
352 also among adults with cardiovascular symptoms. Newly introduced vaccines  
353 might have a high impact, not only on respiratory hospitalization but also on  
354 cardiac hospitalizations.

355

## 356 **Acknowledgements**

### 357 **Funding**

358 This study was funded by Pfizer Ltd.

### 359 **Medical Writing, Editorial, and Other Assistance**

360 Editorial assistance in the preparation of this article was provided by Dr. Somsuvro  
361 Basu of P95. Support for this assistance was funded by Pfizer Ltd.

### 362 **Data availability**

363 The datasets generated and/or analyzed during this study are not publicly  
364 available (data provider's restrictions). Weekly counts of hospitalized cases and  
365 extrapolation factors were provided by the Gesundheitsforen Leipzig GmbH.

366

367

368 **Conflicts of interests**

369 Aleksandra Polkowska-Kramek, Robin Bruyndonckx, Worku Biyadgie Ewnetu,  
370 Pimnara Peerawaranun, Maribel Casas, Thao Mai Phuong Tran are employees of  
371 P95 Epidemiology & Pharmacovigilance, which received funding from Pfizer to  
372 conduct the research described in this manuscript and for manuscript  
373 development. Caihua Liang, Caroline Lade, Lea Johanna Bayer, Bennet Huebbe,  
374 Gordon Brestrich, Christof von Eiff, Bradford D. Gessner, and Elizabeth Begier are  
375 Pfizer employees and may own Pfizer stock. Gernot Rohde is an expert in the field  
376 of RSV and received an honorarium from Pfizer for input on the study design.

377

## 378 **References**

- 379 1. Falsey AR. Respiratory syncytial virus infection in adults. *Semin Respir Crit*  
380 *Care Med* 2007;28:171-81.
- 381 2. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory  
382 syncytial virus infection in elderly and high-risk adults. *N Engl J Med*  
383 2005;352:1749-59.
- 384 3. Falsey AR. Respiratory Syncytial Virus Infection in Elderly Adults. *Drugs*  
385 *Aging* 2005;22:578-87.
- 386 4. Njue A, Nuabor W, Lyall M, Margulis A, Mauskopf J, Curcio D, et al.  
387 Systematic Literature Review of Risk Factors for Poor Outcomes Among Adults  
388 With RSV Infection in High-Income Countries. *Open Forum Infect Dis*  
389 2023;ofad513.
- 390 5. Rozenbaum MH, Begier E, Kurosky SK, Whelan J, Bem D, Pouwels KB, et al.  
391 Incidence of Respiratory Syncytial Virus Infection in Older Adults: Limitations of  
392 Current Data. *Infect Dis Ther* 2023;12:1487-504.
- 393 6. Ramirez J, Carrico R, Wilde A, Junkins A, Furmanek S, Chandler T, et al.  
394 Diagnosis of Respiratory Syncytial Virus in Adults Substantially Increases When  
395 Adding Sputum, Saliva, and Serology Testing to Nasopharyngeal Swab RT-PCR.  
396 *Infect Dis Ther* 2023;12:1593-603.
- 397 7. Onwuchekwa C, Moreo LM, Menon S, Machado B, Curcio D, Kalina W, et al.  
398 Underascertainment of Respiratory Syncytial Virus Infection in Adults Due to  
399 Diagnostic Testing Limitations: A Systematic Literature Review and Meta-analysis.  
400 *J Infect Dis* 2023;228:173-84.
- 401 8. Rozenbaum MH, Judy J, Tran D, Yacisin K, Kurosky SK, Begier E. Low Levels  
402 of RSV Testing Among Adults Hospitalized for Lower Respiratory Tract Infection in  
403 the United States. *Infect Dis Ther* 2023;12:677-85.
- 404 9. McLaughlin JM, Khan F, Begier E, Swerdlow DL, Jodar L, Falsey AR. Rates of  
405 Medically Attended RSV Among US Adults: A Systematic Review and Meta-  
406 analysis. *Open Forum Infect Dis* 2022;9:ofac300.
- 407 10. Fleming DM, Taylor RJ, Lustig RL, Schuck-Paim C, Haguinet F, Webb DJ, et  
408 al. Modelling estimates of the burden of Respiratory Syncytial virus infection in  
409 adults and the elderly in the United Kingdom. *BMC Infect Dis* 2015;15:443.
- 410 11. Ambrosch A, Lubber D, Klawonn F, Kabesch M. Focusing on severe infections  
411 with the respiratory syncytial virus (RSV) in adults: Risk factors, symptomatology  
412 and clinical course compared to influenza A / B and the original SARS-CoV-2  
413 strain. *J Clin Virol* 2023;161:105399.
- 414 12. Branche AR, Saiman L, Walsh EE, Falsey AR, Sieling WD, Greendyke W, et  
415 al. Incidence of Respiratory Syncytial Virus Infection Among Hospitalized Adults,  
416 2017-2020. *Clin Infect Dis* 2022;74:1004-11.
- 417 13. Cai W, Tolksdorf K, Hirve S, Schuler E, Zhang W, Haas W, et al. Evaluation  
418 of using ICD-10 code data for respiratory syncytial virus surveillance. *Influenza*  
419 *Other Respir Viruses* 2020;14:630-7.
- 420 14. Adeli M, El-Shareif T, Hendaus MA. Asthma exacerbation related to viral  
421 infections: An up to date summary. *J Family Med Prim Care* 2019;8:2753-9.
- 422 15. Linden D, Guo-Parke H, Coyle PV, Fairley D, McAuley DF, Taggart CC, et al.  
423 Respiratory viral infection: a potential "missing link" in the pathogenesis of COPD.  
424 *Eur Respir Rev* 2019;28.
- 425 16. Rohde G, Wiethage A, Borg I, Kauth M, Bauer TT, Gillissen A, et al.  
426 Respiratory viruses in exacerbations of chronic obstructive pulmonary disease  
427 requiring hospitalisation: a case-control study. *Thorax* 2003;58:37-42.

- 428 17. Ramaswamy M, Groskreutz DJ, Look DC. Recognizing the importance of  
429 respiratory syncytial virus in chronic obstructive pulmonary disease. *Copd*  
430 2009;6:64-75.
- 431 18. Westerly BD, Peebles RS, Jr. Respiratory syncytial virus infections in the  
432 adult asthmatic--mechanisms of host susceptibility and viral subversion. *Immunol*  
433 *Allergy Clin North Am* 2010;30:523-39, vi-vii.
- 434 19. Ivey KS, Edwards KM, Talbot HK. Respiratory Syncytial Virus  
435 and Associations With Cardiovascular Disease in Adults. *J Am Coll Cardiol*  
436 2018;71:1574-83.
- 437 20. Bosco E, van Aalst R, McConeghy KW, Silva J, Moyo P, Eliot MN, et al.  
438 Estimated Cardiorespiratory Hospitalizations Attributable to Influenza and  
439 Respiratory Syncytial Virus Among Long-term Care Facility Residents. *JAMA*  
440 *network open* 2021;4:e2111806.
- 441 21. Kawashima H, Inagaki N, Nakayama T, Morichi S, Nishimata S, Yamanaka  
442 G, et al. Cardiac Complications Caused by Respiratory Syncytial Virus Infection:  
443 Questionnaire Survey and a Literature Review. *Glob Pediatr Health*  
444 2021;8:2333794x211044114.
- 445 22. Nguyen JL, Yang W, Ito K, Matte TD, Shaman J, Kinney PL. Seasonal  
446 Influenza Infections and Cardiovascular Disease Mortality. *JAMA Cardiol*  
447 2016;1:274-81.
- 448 23. Eisenhut M. Extrapulmonary manifestations of severe respiratory syncytial  
449 virus infection--a systematic review. *Crit Care* 2006;10:R107.
- 450 24. Gkentzi D, Dimitriou G, Karatza A. Non-pulmonary manifestations of  
451 respiratory syncytial virus infection. *J Thorac Dis* 2018;10:S3815-s8.
- 452 25. Franczuk P, Tkaczyszyn M, Kulak M, Domenico E, Ponikowski P, Jankowska  
453 EA. Cardiovascular Complications of Viral Respiratory Infections and COVID-19.  
454 *Biomedicines* 2022;11.
- 455 26. Haeberer M, Bruyndonckx R, Polkowska-Kramek A, Torres A, Liang C,  
456 Nuttens C, et al. Estimated Respiratory Syncytial Virus-Related Hospitalizations  
457 and Deaths Among Children and Adults in Spain, 2016-2019. *Infect Dis Ther*  
458 2024.
- 459 27. Matias G, Taylor RJ, Haguinet F, Schuck-Paim C, Lustig RL, Shinde V.  
460 Estimates of mortality attributable to influenza and RSV in the United States  
461 during 1997-2009 by influenza type or subtype, age, cause of death, and risk  
462 status. *Influenza and other respiratory viruses* 2014;8:507-15.
- 463 28. Goldstein E, Greene SK, Olson DR, Hanage WP, Lipsitch M. Estimating the  
464 hospitalization burden associated with influenza and respiratory syncytial virus in  
465 New York City, 2003-2011. *Influenza Other Respir Viruses* 2015;9:225-33.
- 466 29. Zhou H, Thompson WW, Viboud CG, Ringholz CM, Cheng PY, Steiner C, et  
467 al. Hospitalizations associated with influenza and respiratory syncytial virus in the  
468 United States, 1993-2008. *Clinical infectious diseases : an official publication of*  
469 *the Infectious Diseases Society of America* 2012;54:1427-36.
- 470 30. Li Y, Kulkarni D, Begier E, Wahi-Singh P, Wahi-Singh B, Gessner B, et al.  
471 Adjusting for Case Under-Ascertainment in Estimating RSV Hospitalisation Burden  
472 of Older Adults in High-Income Countries: a Systematic Review and Modelling  
473 Study. *Infect Dis Ther* 2023;12:1137-49.
- 474 31. Polkowska-Kramek A, Begier E, Bruyndonckx R, Liang C, Beese C, Brestrich  
475 G, et al. Estimated Incidence of Hospitalizations and Deaths Attributable to  
476 Respiratory Syncytial Virus Infections Among Adults in Germany Between 2015  
477 and 2019. *Infect Dis Ther* 2024.

- 478 32. Papi A, Ison MG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, et  
479 al. Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults. *N Engl J*  
480 *Med* 2023;388:595-608.
- 481 33. Walsh EE, Pérez Marc G, Zareba AM, Falsey AR, Jiang Q, Patton M, et al.  
482 Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults. *N Engl J*  
483 *Med* 2023;388:1465-77.
- 484 34. Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R).  
485 [https://investors.modernatx.com/news/news-details/2024/Moderna-Receives-](https://investors.modernatx.com/news/news-details/2024/Moderna-Receives-U.S.-FDA-Approval-for-RSV-Vaccine-mRESVIAR/default.aspx)  
486 [U.S.-FDA-Approval-for-RSV-Vaccine-mRESVIAR/default.aspx](https://investors.modernatx.com/news/news-details/2024/Moderna-Receives-U.S.-FDA-Approval-for-RSV-Vaccine-mRESVIAR/default.aspx).
- 487 35. GmbH GL. Deutsche Analysedatenbank für Evaluation und  
488 Versorgungsforschung, Stand Januar. 2022.  
489 [https://www.gesundheitsforen.net/GFL/Services/Analytik/Gesundheitsforen%20Le](https://www.gesundheitsforen.net/GFL/Services/Analytik/Gesundheitsforen%20Leipzig_DADB_Q1%202024.pdf)  
490 [ipzig\\_DADB\\_Q1%202024.pdf](https://www.gesundheitsforen.net/GFL/Services/Analytik/Gesundheitsforen%20Leipzig_DADB_Q1%202024.pdf). Date last accessed: 19.04.2024 2024.
- 491 36. Oh DY, Buda S, Biere B, Reiche J, Schlosser F, Duwe S, et al. Trends in  
492 respiratory virus circulation following COVID-19-targeted nonpharmaceutical  
493 interventions in Germany, January - September 2020: Analysis of national  
494 surveillance data. *Lancet Reg Health Eur* 2021;6:100112.
- 495 37. Zheng Z, Warren JL, Shapiro ED, Pitzer VE, Weinberger DM. Estimated  
496 incidence of respiratory hospitalizations attributable to RSV infections across age  
497 and socioeconomic groups. *Pneumonia (Nathan)* 2022;14:6.
- 498 38. Casiano-Colón AE, Hulbert BB, Mayer TK, Walsh EE, Falsey AR. Lack of  
499 sensitivity of rapid antigen tests for the diagnosis of respiratory syncytial virus  
500 infection in adults. *J Clin Virol* 2003;28:169-74.
- 501 39. Calvo C, Pozo F, García-García ML, Sanchez M, Lopez-Valero M, Pérez-Breña  
502 P, et al. Detection of new respiratory viruses in hospitalized infants with  
503 bronchiolitis: a three-year prospective study. *Acta Paediatr* 2010;99:883-7.
- 504 40. Mansbach JM, Piedra PA, Teach SJ, Sullivan AF, Forgey T, Clark S, et al.  
505 Prospective multicenter study of viral etiology and hospital length of stay in  
506 children with severe bronchiolitis. *Arch Pediatr Adolesc Med* 2012;166:700-6.
- 507 41. Kenmoe S, Kengne-Nde C, Ebogo-Belobo JT, Mbaga DS, Fatawou Modiyinji  
508 A, Njouom R. Systematic review and meta-analysis of the prevalence of common  
509 respiratory viruses in children < 2 years with bronchiolitis in the pre-COVID-19  
510 pandemic era. *PLoS One* 2020;15:e0242302.
- 511 42. Bruyndonckx R, Polkowska-Kramek A, Liang C, Nuttens C, Tran TMP,  
512 Gessner BD, et al. Estimation of Symptomatic Respiratory Syncytial Virus Infection  
513 Incidence in Adults in Multiple Countries: A Time-Series Model-Based Analysis  
514 Protocol. *Infect Dis Ther* 2024.
- 515 43. Good Epidemiological Practice. Guidelines for Proper Conduct of  
516 Epidemiological Research, (2007).
- 517 44. Niekler P, Goettler D, Liese JG, Streng A. Hospitalizations due to respiratory  
518 syncytial virus (RSV) infections in Germany: a nationwide clinical and direct cost  
519 data analysis (2010-2019). *Infection* 2023.
- 520 45. Meier CR, Jick SS, Derby LE, Vasilakis C, Jick H. Acute respiratory-tract  
521 infections and risk of first-time acute myocardial infarction. *Lancet*  
522 1998;351:1467-71.
- 523 46. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of  
524 myocardial infarction and stroke after acute infection or vaccination. *N Engl J Med*  
525 2004;351:2611-8.
- 526 47. Vallance P, Collier J, Bhagat K. Infection, inflammation, and infarction: does  
527 acute endothelial dysfunction provide a link? *Lancet* 1997;349:1391-2.

- 528 48. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM,  
529 et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019:  
530 Update From the GBD 2019 Study. *J Am Coll Cardiol* 2020;76:2982-3021.
- 531 49. Zangiabadian M, Nejadghaderi SA, Mirsaedi M, Hajikhani B, Goudarzi M,  
532 Goudarzi H, et al. Protective effect of influenza vaccination on cardiovascular  
533 diseases: a systematic review and meta-analysis. *Sci Rep* 2020;10:20656.
- 534 50. Nichol KL, Nordin J, Mullooly J, Lask R, Fillbrandt K, Iwane M. Influenza  
535 vaccination and reduction in hospitalizations for cardiac disease and stroke among  
536 the elderly. *N Engl J Med* 2003;348:1322-32.
- 537 51. Hanquet G, Theilacker C, Vietri J, Sepúlveda-Pachón I, Menon S, Gessner B,  
538 et al. Best Practices for Identifying Hospitalized Lower Respiratory Tract Infections  
539 Using Administrative Data: A Systematic Literature Review of Validation Studies.  
540 *Infect Dis Ther* 2024;13:921-40.
- 541 52. Wiseman DJ, Thwaites RS, Ritchie AI, Finney L, Macleod M, Kamal F, et al.  
542 RSV-related Community COPD Exacerbations and Novel Diagnostics: A Binational  
543 Prospective Cohort Study. *Am J Respir Crit Care Med* 2024.
- 544 53. Colosia AD, Yang J, Hillson E, Mauskopf J, Copley-Merriman C, Shinde V, et  
545 al. The epidemiology of medically attended respiratory syncytial virus in older  
546 adults in the United States: A systematic review. *PLoS One* 2017;12:e0182321.
- 547 54. Agarwal D. COPD generates substantial cost for health systems. *Lancet Glob*  
548 *Health* 2023;11:e1138-e9.
- 549 55. Chen S, Kuhn M, Prettner K, Yu F, Yang T, Bärnighausen T, et al. The global  
550 economic burden of chronic obstructive pulmonary disease for 204 countries and  
551 territories in 2020-50: a health-augmented macroeconomic modelling study.  
552 *Lancet Glob Health* 2023;11:e1183-e93.
- 553 56. Melgar M, Britton A, Roper LE, Talbot HK, Long SS, Kotton CN, et al. Use of  
554 Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the  
555 Advisory Committee on Immunization Practices - United States, 2023. *MMWR*  
556 *Morb Mortal Wkly Rep* 2023;72:793-801.
- 557
- 558
- 559
- 560
- 561
- 562
- 563
- 564
- 565
- 566
- 567

## Tables

**Table 1 Estimated incidence rate per 100,000 person-years of RSV-attributable respiratory hospitalizations and percentage (%) of all respective respiratory hospitalizations attributable to RSV infections in adults in Germany, 2015-2019**

Age groups	2015		2016		2017		2018		2019	
	IR [95% CI]	%	IR [95% CI]	%	IR [95% CI]	%	IR [95% CI]	%	IR [95% CI]	%
<b>Influenza/pneumonia</b>										
18-44	2.7 [0, 6.0]	2.9	4.2 [0, 9.1]	3.6	4.8 [0, 10.4]	4.4	3.8 [0, 8.4]	3.1	5.0 [0, 11.0]	4.6
45-59	3.3 [0, 8.1]	1.3	4.8 [0, 11.8]	1.8	5.2 [0, 13.0]	1.9	4.1 [0, 10.3]	1.4	5.5 [0, 13.6]	2.0
60-74	20.4 [0, 42.6]	1.9	20.8 [0, 43.6]	1.8	27.7 [0, 57.9]	2.4	18.1 [0, 37.9]	1.6	23.9 [0, 50.0]	2.2
≥75	231.3 [137.4, 330.0]	4.3	253.7 [150.7, 362.0]	4.5	292.4 [173.7, 417.2]	5.1	205.8 [122.3, 293.7]	3.6	273.9 [162.7, 390.8]	5.0
≥60*	73.7	3.4	81.0	3.5	97.9	4.1	67	2.8	88.4	3.9
<b>Bronchitis/bronchiolitis</b>										
18-44	0.4 [0, 2.7]	0.9	0.5 [0, 3.3]	1.0	0.6 [0, 4.5]	1.4	0.4 [0, 3.2]	0.9	0.6 [0, 4.3]	1.5
45-59	6.6 [3.4, 10.1]	8.6	7.7 [4.0, 11.9]	9.2	10.0 [5.2, 15.4]	11.0	6.9 [3.6, 10.7]	7.8	9.7 [5.0, 14.9]	11.1
60-74	25.5 [14.9, 35.8]	9.0	24.1 [14.1, 33.9]	8.8	34.4 [20.1, 48.4]	11.8	21.2 [12.4, 29.8]	7.3	28.5 [16.7, 40.1]	10.9
≥75	283.6 [222.9, 343.8]	19.6	281.9 [221.6, 341.8]	20.1	359.8 [282.8, 436.3]	22.4	234.4 [184.2, 284.2]	16.6	314.2 [247.0, 381.0]	24.5
≥60*	91.3	15.5	91.5	15.9	121.8	18.7	77.2	13.1	102.9	19.3
<b>Chronic lower respiratory tract diseases</b>										
18-44	NA		NA		NA		NA		NA	
45-59	18.9 [1.7, 35.5]	2.4	17.4 [1.5, 32.7]	2.0	28.1 [2.5, 52.8]	3.1	17.5 [1.6, 32.9]	2.0	25.4 [2.3, 47.8]	2.9
60-74	74.4 [17.2, 133.8]	2.4	70.4 [16.3, 126.6]	2.1	100.5 [23.2, 180.7]	3.0	61.8 [14.3, 111.2]	1.9	83.3 [19.2, 149.8]	2.6
≥75	279.5 [125.7, 432.5]	3.3	239.0 [107.5, 369.8]	2.6	342.7 [154.1, 530.3]	3.9	211.4 [95.1, 327.1]	2.6	293.0 [131.7, 453.3]	3.6
≥60*	128.9	2.8	116.7	2.3	168.2	3.4	102.9	2.2	140.1	3.1
<b>Upper respiratory tract diseases</b>										
18-44	10.9 [0, 27.3]	1.7	10.4 [0, 26.1]	1.5	17.4 [0, 43.7]	2.4	11.1 [0, 27.8]	1.6	15.8 [0, 39.7]	2.3

Age groups	2015		2016		2017		2018		2019	
	IR [95% CI]	%	IR [95% CI]	%	IR [95% CI]	%	IR [95% CI]	%	IR [95% CI]	%
45-59	8.2 [0, 21.7]	1.9	8.1 [0, 21.3]	1.7	12.4 [0, 32.9]	2.5	8.0 [0, 21.1]	1.7	11.4 [0, 30.1]	2.4
60-74	18.6 [0.4, 35.5]	3.6	17.6 [0.4, 33.6]	3.1	25.1 [0.6, 48.0]	4.4	15.4 [0.4, 29.5]	2.8	20.8 [0.5, 39.8]	3.9
≥75	55.9 [25.7, 86.4]	7.2	51.2 [23.5, 79.1]	6.4	70.0 [32.2, 108.2]	8.4	44.5 [20.4, 68.7]	5.5	60.6 [27.8, 93.5]	8.1
≥60*	28.7	4.8	26.9	4.1	37.9	5.8	23.5	3.7	31.7	5.2

*CI: confidence interval; IR: incidence rate extrapolated to the national level; NA: not applicable due to data not suitable for modeling*

*\* Based on pooling results for models fitted to adults for included age groups, thus confidence intervals are not provided.*

**Table 2 Estimated incidence rate per 100,000 person-years of RSV-attributable cardiovascular hospitalizations and percentage (%) of all respective cardiovascular hospitalizations attributable to RSV infections in adults in Germany, 2015-2019**

Age groups	2015		2016		2017		2018		2019	
	IR [95% CI]	%	IR [95% CI]	%	IR [95% CI]	%	IR [95% CI]	%	IR [95% CI]	%
<b>Chronic heart failure exacerbation</b>										
18-44	NA		NA		NA		NA		NA	
45-59	NA		NA		NA		NA		NA	
60-74	65.9 [14.3, 117.0]	2.3	58.2 [12.6, 103.4]	1.9	87.1 [18.9, 154.6]	2.8	52.1 [11.3, 92.4]	1.8	71.4 [15.5, 126.7]	2.4
≥75	302.5 [76.6, 542.1]	1.9	300.7 [76.2, 538.8]	1.8	383.8 [97.2, 687.8]	2.3	250.0 [63.3, 448.1]	1.5	335.1 [84.9, 600.6]	2.1
≥60*	127.9	2.0	123.0	1.8	168.7	2.5	105.3	1.6	141.7	2.2
<b>Ischemic heart diseases</b>										
18-44	NA		NA		NA		NA		NA	
45-59	15.4 [0, 34.0]	1.6	15.2 [0, 33.5]	1.5	23.3 [0, 51.5]	2.2	15.0 [0, 33.1]	1.5	21.4 [0, 47.2]	2.1
60-74	92.1 [0.6, 175.4]	1.8	87.2 [0.6, 166.0]	1.6	124.4 [0.8, 236.8]	2.5	76.5 [0.5, 145.7]	1.6	103.1 [0.7, 196.3]	2.1
≥75	357.9 [47.9, 672.1]	1.9	327.7 [43.9, 615.5]	1.6	448.2 [60.0, 841.8]	2.3	284.5 [38.1, 534.4]	1.5	387.5 [51.9, 727.9]	2.1
≥60*	162.5	2.0	152.6	1.8	214.5	2.5	133.3	1.6	179.8	2.2
<b>Arrhythmia</b>										
18-44	NA		NA		NA		NA		NA	
45-59	16.3 [1.8, 31.8]	2.5	15.0 [1.7, 29.2]	2.0	24.2 [2.7, 47.2]	3.1	15.1 [1.7, 29.5]	2.0	22.0 [2.5, 42.8]	2.9
60-74	108.7 [26.5, 175.8]	2.6	96.1 [23.5, 155.4]	2.2	143.7 [35.1, 232.4]	3.3	85.9 [21.0, 138.9]	2.1	117.8 [28.7, 190.5]	2.8
≥75	460.9 [118.3, 786.7]	2.1	394.2 [101.1, 672.8]	1.6	565.2 [145.0, 964.6]	2.4	348.6 [89.5, 595.0]	1.5	483.1 [124.0, 824.5]	2.0
≥60*	201.5	2.3	176.6	1.8	260.4	2.7	157.2	1.7	215.8	2.3
<b>Cerebrovascular diseases</b>										
18-44	NA		NA		NA		NA		NA	
45-59	NA		NA		NA		NA		NA	
60-74	NA		NA		NA		NA		NA	
≥75	97.6 [9.9, 189.7]	1.7	83.5 [8.5, 162.2]	1.4	119.7 [12.1, 232.6]	2.0	73.9 [7.5, 143.5]	1.3	102.3 [10.4, 198.8]	1.9

CI: confidence interval; IR: incidence rate extrapolated to the national level; NA: not applicable due to data not suitable for modeling

\* Based on pooling results for models fitted to adults for included age groups, thus confidence intervals are not provided.